Balanced news tone
News Sentiment
PYC sentiment intelligence
PYC Therapeutics Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
93/100 classification confidence.
directly relevant articles
high-authority source matches
+1.3% over one week, +27.5% over four weeks, trend inactive, and materially above fair value.
PYC Therapeutics (ASX:PYC) Eases While Holding on to Positive One-Year Returns
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
PYC Therapeutics (ASX:PYC) Eases While Holding on to Positive One-Year Returns
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 10:09
- Source
- Kalkine
PYC Therapeutics (ASX:PYC) Slips as Investors Assess the Emerging RNA-Therapeutics Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 08:16
- Source
- Kalkine
PYC Therapeutics (ASX:PYC) Names New CFO As Investors Weigh A Pricey Valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 23:26
- Source
- simplywall.st
Can PYC Therapeutics (ASX:PYC) Strengthen Its Growth Strategy With a New CFO?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 03:59
- Source
- Kalkine Media
Will PYC Therapeutics’ New CFO Shift Its Capital-Market Ambitions Up a Gear (ASX:PYC)?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 16:36
- Source
- simplywall.st
Pyc Therapeutics Limited Announces Appointment of Thomas Ulmer as Chief Financial Officer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 22:21
- Source
- marketscreener.com
PYC Therapeutics (ASX:PYC) Shares Ease Lower Amid Biotech Sector Watch
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- Kalkine
PYC Therapeutics Limited Actuals & Estimates (ASX:PYC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 17:43
- Source
- TradingView
Pleasing Signs As A Number Of Insiders Buy PYC Therapeutics Stock
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- simplywall.st
PYC Stock Price and Chart — ASX:PYC
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- TradingView
PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- simplywall.st
PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Feb 2026 08:00
- Source
- Stocks Down Under
PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Feb 2026 08:00
- Source
- BiotechDispatch
Health Check: PYC Therapeutics kicks off monster $650m capital raising
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- Stockhead
PYC Therapeutics launches $600m-plus cash call, hires two banks
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Feb 2026 08:00
- Source
- AFR
When Will PYC Therapeutics Limited (ASX:PYC) Become Profitable?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jan 2026 08:00
- Source
- Market source
Why PYC Therapeutics (ASX:PYC) Is Down 14.4% After Sudden CEO Exit and Board Reshuffle
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Sep 2025 07:00
- Source
- Market source
WA Rich Lister Alan Tribe takes reins at PYC Therapeutics as CEO Rohan Hockings abruptly quits
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Sep 2025 07:00
- Source
- The West Australian